Adoptive Cell Therapy Against Triple-Negative Breast Cancer Using a Novel tMUC1 Antibody-Derived CAR
Abstract
In the previous report, most of Tasks 1, 2, and 3 (Aim 1) were completed. In brief, post approval for IACUC and IRB protocols, we completed the development of the2nd and 3rd generation human CAR constructs, confirmed the sequences, generated the CAR T cells, and successfully completed cytolysis assays against TNBC cell lines in an antigen-specific manner without any toxic effects to normal epithelial cells. We initiated the in vivo experiments outlined in specific aim 2. Most of the data is now published. In this cycle, we report the progress made in Tasks 3 through 7. We show the efficacy of CAR T + anti-PD1 blocking antibody treatment in the NSG mouse model of human TNBC. We have successfully generated the murine CAR t cells and conducted in vitro functional assays using murine breast cancer cell lines. We also report on the efficacy of murine CAR t cells in an immune competent spontaneous PyVMT tumor model in vivo. Due to COVID related lockdown, we did face challenges that were beyond our control.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1134745
Entities
People
- Pinku Mukherjee
Organizations
- University of North Carolina at Charlotte